AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03697070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: INSPIRE CPOE Smart Prompt
Description: Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having PNA due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards.
Study NCT03697070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
Study NCT04544436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total).
Study NCT04544436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.
Study NCT04544436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihistamine
Description: Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
Study NCT04544436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
Study NCT04544436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
Study NCT04544436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
Study NCT02672917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: intravenous infusion (IV)
Study NCT02672917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified FOLFIRINOX (mFOLFIRINOX)
Description: IV
Study NCT02672917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine + nab-paclitaxel
Description: IV
Study NCT02587897 — intervention group
Intervention type: OTHER
Intervention: Academic Coursework
Description: Didactic training provided by the university through coursework and laboratory training that meets requirements of the accreditation standards provided by the professional society associated with each professional degree granting program.
Study NCT02587897 — intervention group
Intervention type: OTHER
Intervention: Work-Related Hand Activities
Description: Exposure to intensive training in the use of dental scaling tools as part of laboratory courses, as well as fieldwork and residency training during the academic degree program.
Study NCT03075254 — intervention group
Intervention type: DEVICE
Intervention: A Peltier for Sensory testing
Description: Subjects will be trained to rate the magnitude of late sensations elicited following brief (700 msec) contact of a preheated thermode with the glabrous (palmar) skin of either hand/foot either numerically or using a visual analogue scale.
Study NCT03075254 — intervention group
Intervention type: DEVICE
Intervention: functional magnetic resonance imaging for Brain Neuroimaging
Description: to evaluate baseline changes in regional cerebral blood flow to nociceptive thermal stimuli applied to the extremities of FM patients and healthy volunteers.
Study NCT02727803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Natural Killer Cell Line NK-92
Description: Given IV
Study NCT02727803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV
Study NCT02727803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT02727803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV
Study NCT02727803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02727803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02727803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02727803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT02727803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02727803 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total body irradiation
Study NCT02727803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo umbilical cord blood transplantation
Study NCT02774785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MarginProbe
Description: Surgery to take place as per standard care. When the surgery is nearly concluded, patient to be randomised. If randomised to device arm, the MarginProbe device will be used on the outer edge of the tumour and shavings. If the MarginProbe device indicates that cancer is detected, a further shaving is to be taken. Surgery then to be concluded as per standard care.
Study NCT03274687 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Description: 66.6 Gy in 37 daily fractions of 1.8 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
Study NCT03274687 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiation therapy
Description: 62.5 Gy in 25 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
Study NCT03274687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optional androgen deprivation therapy
Description: Any luteinizing hormone-releasing hormone (LHRH) agonist/antagonist with or without an oral antiandrogen can be used up to a six-month administration dose, starting 7-9 weeks before radiation therapy and may begin as early as 42 days prior to or any time after screening. An oral antiandrogen alone is not allowed.
Study NCT03274687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional androgen deprivation therapy
Description: Any luteinizing hormone-releasing hormone (LHRH) agonist/antagonist with or without an oral antiandrogen can be used up to a six-month administration dose, starting 7-9 weeks before radiation therapy and may begin as early as 42 days prior to or any time after screening. An oral antiandrogen alone is not allowed.
Study NCT03079024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Cognitive Training
Description: 1. Auditory Training Module (20 hours): exercises designed to improve speed and accuracy of auditory processing while engaging working memory and cognitive control. Exercises adjust difficulty level to maintain an \~80% correct performance. Exercises contain stimuli spanning the acoustic organization of speech. In the initial stages, stimuli exaggerate the rapid temporal transitions by increasing amplitude and stretching in time. The exaggeration is gradually removed so that by the end, all stimuli have characteristics representative of real-world speech.~2. Social Cognition Module (10 hours): exercises designed to improve core deficits of social cognition in psychosis. Exercises apply principles of implicit learning to restore capacity to process and utilize socially-relevant information, and includes training to improve perception of affect (visual/vocal) and social cues (faces, gazes, social situations), theory of mind, self-referential style, emotion labeling and working memory.
Study NCT03079024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General Cognitive Exercises
Description: The GCE will focus on executive dysfunction, as this domain is a significant, functionally important area of deficit in schizophrenia and has been the target of many previous studies. We will train this domain using a suite of engaging, adaptive web-based exercises that target executive function, intelligence, and spatial navigation developed by Posit Science. The exercises will be provide engaging, adaptive training as described in the Targeted Cognitive Training.
Study NCT03079024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinated Specialty Care for First Episode Psychosis
Description: Individuals in this study are receiving care from a coordinated specialty care clinic (CSC) for first episode psychosis. These clinics are following the NAVIGATE treatment model for early psychosis.
Study NCT03079024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coordinated Specialty Care for First Episode Psychosis
Description: Individuals in this study are receiving care from a coordinated specialty care clinic (CSC) for first episode psychosis. These clinics are following the NAVIGATE treatment model for early psychosis.
Study NCT00601627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00601627 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04115930 — intervention group
Intervention type: DEVICE
Intervention: Physical Activity measurement:
Description: 7 days measurement with Active style Pro HJA-350IT device
Study NCT01071226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS (CD+3, CD+19 depletion)
Description: Patient's in Stratum 1 will receive grafts that have undergone CD3+, CD19+ depletion
Study NCT01071226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS (CD 34+ positive selection)
Description: Patient's in Stratum 2 will receive peripheral blood progenitor cells that have undergone CD34+ selection
Study NCT01071226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCT
Description: Peripheral Blood Stem Cell Transplant
Study NCT04360135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Preemptive acetaminophen the day before surgery
Study NCT04360135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preemptive placebo the day before surgery
Study NCT04605770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed+cisplatin
Description: Pemetrexed 500 mg/m2 (Day 1) and cisplatin 75 mg/m2 (Day 1) will be given via intravenous (IV) infusion. Each cycle consists of 21 days, and this combination therapy will be continued until Cycle 6. Starting from Cycle 7, pemetrexed alone will be administered every 3 weeks (Q3W) as IV infusion until disease progression.~Vitamin B12 1000 mcg intramuscular (IM) injection will be given within 14 days prior to the first dose of pemetrexed, every 9 weeks (on the same day as study treatment) thereafter, and then 21 days after the last dose of pemetrexed. Folic acid 1 mg will be administered daily starting from 14 days before the first dose of pemetrexed and continued until 21 days after the last dose of pemetrexed. Study treatment will be continued until PD, unacceptable AE, or decision to discontinue by subject or physician.
Study NCT01848834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT01237691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE supervision
Description: HOPE entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). HOPE includes regular random drug testing.
Study NCT01237691 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parole-as-usual
Description: Parolees are supervised under standard parole supervision practice in California.
Study NCT02324660 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: screening test
Description: screening test with peak expiratory flow and respiratory health screening questionnaire to discriminate patients at risk for COPD
Study NCT02056691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise programme
Description: The exercise regime consists of 10 sessions of exercise against a constant load, each lasting 60 seconds, separated by 60 seconds of recovery eliciting 90% maximal heart rate. The 6 sessions are held over a 2 week period.
Study NCT02056691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: muscle biopsy under local anaesthetic taken from the thigh, again for analysis and storage 3 times: before, during and after the exercise programme
Study NCT04521218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust Joint Manipulation
Description: Experimental group included TJM, Cervical hot pack, strengthening exercises and home plan; 3 sessions of manipulation per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold.
Study NCT04521218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reverse Sustained Natural apophyseal glides
Description: Control group included Moist Hot Pack (Cervical contour- 8.25 x 10 x 2) for 10 Mins, Reverse SNAGS (10 Repetitions holding for 10 sec in each glide with a rest time of 30 seconds in between), Strengthening exercise and home plan. 3 sessions of mobilization per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold
Study NCT01498172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A3 ASCI
Description: 5 doses every 3 weeks
Study NCT01498172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: 1 intravesical dose /week for 6 weeks
Study NCT00471133 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Xenogeneic Tyrosinase DNA Vaccine
Study NCT00471133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriGrid Delivery System for Intramuscular Electroporation
Study NCT03244553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: 5 day treatment
Study NCT03186976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aggressive Risk Factor Control
Description: 1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2) Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (>5 drinks at one setting).~3) Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4) An OMRON BP monitor will be supplied to each patient. A target SBP of \<140/80 mm/Hg will be targeted.~5) Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c\<6.5%
Study NCT03186976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Recommendations based on current guidelines
Study NCT01910688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA treatment
Description: If eligible for enrollment, a focal ablation device is selected as an intervention(size according to physician preference) and mounted on the end of the endoscope and introduced via the mouth into the esophagus and gastric pouch. The gastric pouch is treated from the top of the gastric folds to and just through the stomal anastomosis.
Study NCT03596294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Continuous i.v. infusion of 15 mg/h of clazosentan for 3 h
Study NCT03596294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Single i.v. dose of 600 mg rifampicin for 30 min
Study NCT02478671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TR Band
Description: The radial artery will be compressed using a Terumo TR Band and artery diameter and perfusion will be measured
Study NCT02534961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms.
Study NCT03345004 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diamyd
Description: Alhydrogel®-formulated recombinant human glutamic acid decarboxylase (rhGAD65)
Study NCT03345004 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Oil suspension of Vitamin D
Study NCT03345004 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Diamyd
Description: Alhydrogel® only
Study NCT03345004 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Vitamin D
Description: Placebo oil suspension for Vitamin D
Study NCT04649723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: single oral dose, 600 mg, fasted.
Study NCT04649723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459
Description: single oral dose, 200 mg, fasted.
Study NCT04649723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR1459
Description: single oral dose, 200 mg, fasted.
Study NCT01531179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri 100 million CFU/day for 3 months
Study NCT01531179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 months
Study NCT01599962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: single administration, 90mg
Study NCT01599962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cinacalcet
Description: single administration, 90mg
Study NCT01599962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single administration
Study NCT02837653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Counselling
Study NCT02837653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise for LBP
Study NCT02837653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise for LBP
Study NCT02837653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Superficial Thermotherapy
Study NCT02837653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Superficial Thermotherapy
Study NCT02260986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
Study NCT02260986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Dupilumab)
Description: Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
Study NCT02260986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroid (TCS)
Description: All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.
Study NCT03175458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus lift,implant placement,tenting
Description: elevation of the sinus membrane then insertion of the implants without any bone graft material( graft-less) for augmentation